Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET G691S |
Therapy | Dovitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET G691S | Advanced Solid Tumor | predicted - sensitive | Dovitinib | Case Reports/Case Series | Actionable | In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625). | 25103625 |
PubMed Id | Reference Title | Details |
---|---|---|
(25103625) | Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial. | Full reference... |